Moderna (MRNA) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free MRNA Stock Alerts $142.55 -8.94 (-5.90%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 9:45 AM | marketbeat.comLetko Brosseau & Associates Inc. Invests $31.77 Million in Moderna, Inc. (NASDAQ:MRNA)Letko Brosseau & Associates Inc. purchased a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 319,430 shares of the company's stock, valued at approximately $31,767,000.June 1 at 8:36 AM | insidertrades.comNoubar Afeyan Sells 20,000 Shares of Moderna, Inc. (NASDAQ:MRNA) StockJune 1 at 8:02 AM | insidertrades.comStephen Hoge Sells 341 Shares of Moderna, Inc. (NASDAQ:MRNA) StockMay 31 at 11:06 PM | seekingalpha.comModerna, Inc. (MRNA) Bernstein's 40th Annual Strategic Decisions Conference (Transcript)May 31 at 11:53 AM | investors.comModerna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSKMay 31 at 11:09 AM | cnbc.comFDA approves Moderna's RSV vaccine for seniors, the company's second-ever productMay 31 at 11:06 AM | reuters.comUS FDA approves Moderna's RSV vaccine, its second marketed productMay 31 at 7:00 AM | investorplace.com3 Sorry Biotech Stocks to Sell in May While You Still CanMay 30 at 4:40 PM | marketbeat.comModerna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 341 SharesModerna, Inc. (NASDAQ:MRNA - Get Free Report) President Stephen Hoge sold 341 shares of Moderna stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $144.50, for a total transaction of $49,274.50. Following the completion of the transaction, the president now owns 1,471,777 shares in the company, valued at approximately $212,671,776.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.May 30 at 4:21 PM | fool.comWhy Moderna Stock Is Sinking This WeekMay 30 at 9:40 AM | americanbankingnews.comModerna (NASDAQ:MRNA) Stock Price Down 6.2%May 30 at 9:22 AM | investors.comModerna Pops After Confirming The U.S. Government Could Back Its Bird Flu VaccineMay 30 at 9:02 AM | americanbankingnews.comModerna, Inc. (NASDAQ:MRNA) Insider Shannon Thyme Klinger Sells 1,296 Shares of StockMay 30 at 8:20 AM | americanbankingnews.comModerna, Inc. (NASDAQ:MRNA) CFO James M. Mock Sells 648 SharesMay 30 at 8:18 AM | insidertrades.comModerna, Inc. (NASDAQ:MRNA) CFO Sells $105,280.56 in StockMay 30 at 6:57 AM | marketbeat.comAdvisory Services Network LLC Buys 5,667 Shares of Moderna, Inc. (NASDAQ:MRNA)Advisory Services Network LLC raised its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 80.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,715 shares of the company's stock after buying an additional 5,667 shareMay 30 at 6:00 AM | investorplace.com3 Nasdaq Stocks to Dump as They Near Peak PerformanceMay 30 at 12:51 AM | reuters.comUS nears deal to fund Moderna's bird flu vaccine trial, FT reportsMay 29 at 7:48 PM | marketbeat.comInsider Selling: Moderna, Inc. (NASDAQ:MRNA) CFO Sells $105,280.56 in StockModerna, Inc. (NASDAQ:MRNA - Get Free Report) CFO James M. Mock sold 648 shares of the business's stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $105,280.56. Following the completion of the sale, the chief financial officer now owns 5,726 shares of the company's stock, valued at $930,303.22. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.May 29 at 7:20 PM | ca.news.yahoo.comArticle reported on rising cancer rates before pandemic, didn't link to vaccines | Fact checkMay 29 at 9:19 AM | finance.yahoo.commRNA Therapeutics Market Report 2024-2030: A Projected $31.3 Billion Opportunity Dominated by Moderna, BioNTech, and CureVacMay 29 at 6:30 AM | investorplace.comIf You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 NamesMay 28, 2024 | barrons.comModerna Shares Had a Bad Day. Here's Why.May 28, 2024 | marketbeat.comEdmond DE Rothschild Holding S.A. Sells 12,149 Shares of Moderna, Inc. (NASDAQ:MRNA)Edmond DE Rothschild Holding S.A. lessened its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 10.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 109,363 shares of the company's stock after selling 12,149 sharMay 28, 2024 | marketbeat.comModerna (NASDAQ:MRNA) Shares Down 6.2% Moderna (NASDAQ:MRNA) Shares Down 6.2%May 28, 2024 | americanbankingnews.comZacks Research Weighs in on Moderna, Inc.'s Q2 2024 Earnings (NASDAQ:MRNA)May 27, 2024 | marketbeat.comIntech Investment Management LLC Sells 77,684 Shares of Moderna, Inc. (NASDAQ:MRNA)Intech Investment Management LLC cut its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 75.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,196 shares of the company'sMay 27, 2024 | americanbankingnews.comModerna, Inc. (NASDAQ:MRNA) Receives Average Rating of "Hold" from BrokeragesMay 27, 2024 | marketbeat.comZacks Research Analysts Cut Earnings Estimates for Moderna, Inc. (NASDAQ:MRNA)Moderna, Inc. (NASDAQ:MRNA - Free Report) - Investment analysts at Zacks Research reduced their Q2 2024 earnings per share (EPS) estimates for shares of Moderna in a note issued to investors on Thursday, May 23rd. Zacks Research analyst S. Ganoria now expects that the company will post earnings oMay 26, 2024 | marketbeat.comNeuberger Berman Group LLC Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)Neuberger Berman Group LLC boosted its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 7.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 126,643 shares of the company's stock after buying an additiMay 26, 2024 | fool.comShould You Buy This Stock After a Regulatory Setback?May 26, 2024 | americanbankingnews.comModerna, Inc. (NASDAQ:MRNA) Director Sells $2,363,550.00 in StockMay 25, 2024 | marketbeat.comOntario Teachers Pension Plan Board Buys Shares of 13,657 Moderna, Inc. (NASDAQ:MRNA)Ontario Teachers Pension Plan Board acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 13,657 shares of the company's stock, valued at approximately $1,358,000. OtMay 25, 2024 | insidertrades.comModerna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 SharesMay 25, 2024 | americanbankingnews.comModerna (NASDAQ:MRNA) Shares Gap Down to $163.33May 24, 2024 | barrons.comCancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.May 24, 2024 | marketbeat.comD.A. Davidson & CO. Purchases 22,988 Shares of Moderna, Inc. (NASDAQ:MRNA)D.A. Davidson & CO. boosted its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 227.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,101 shares of the company's stock after acquiring an additional 22,May 24, 2024 | fool.comWhy Vaccine Stocks Rallied This WeekMay 23, 2024 | investing.comVaccine stocks gain, Moderna and Pfizer in talks with the US on bird flu vaccinesMay 23, 2024 | seekingalpha.comModerna: Betting On Bird Flu Rally Is A Poor Strategy For A Value InvestorMay 23, 2024 | investorplace.comThe Moderna News That Has MRNA Stock Price Surging: 3 Key CatalystsMay 22, 2024 | msn.comPfizer, Moderna in talks with HHS over avian flu vaccine: reportMay 22, 2024 | benzinga.comOracle, Moderna, Palantir Technologies And A Big Bank On CNBC's 'Final Trades'May 22, 2024 | finance.yahoo.comModerna Announces Data to be Presented at 2024 ASCO Annual MeetingMay 22, 2024 | fool.comModerna Has Big AI News. Is the Stock a Buy?May 21, 2024 | msn.comModerna trades in the green for seventh straight sessionMay 21, 2024 | marketbeat.comModerna (NASDAQ:MRNA) Sets New 52-Week High at $143.87Moderna (NASDAQ:MRNA) Hits New 1-Year High at $143.87May 21, 2024 | finance.yahoo.comSelling US$3.3m Of Moderna Stock Rewarded InsidersMay 21, 2024 | msn.comInvestor Interest Peaks in Moderna, Inc. (MRNA): Here’s What You Need to KnowMay 21, 2024 | marketbeat.comAssetmark Inc. Increases Stake in Moderna, Inc. (NASDAQ:MRNA)Assetmark Inc. boosted its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 187.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 619,152 shares of the company's stock after buying an additional 403,428 shar Get Moderna News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s arrest is phase one (Ad)In this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… To get all the details, go here now. MRNA Media Mentions By Week MRNA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRNA News Sentiment▼0.520.78▲Average Medical News Sentiment MRNA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRNA Articles This Week▼4219▲MRNA Articles Average Week Get Moderna News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Seagen News Amgen News Gilead Sciences News Biogen News BioNTech News argenx News Neurocrine Biosciences News Bio-Techne News Qiagen News Repligen News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRNA) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
